<DOC>
	<DOCNO>NCT01454024</DOCNO>
	<brief_summary>This study conduct Asia . The aim study evaluate safety NovoPen® 3 and/or FlexPen® device ( available market ) measure number adverse event technical complaint patient type 1 type 2 diabetes routine clinical practice .</brief_summary>
	<brief_title>Evaluating Safety NovoPen® 3 and/or FlexPen® Devices Routine Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Any subject previously use Actrapid® , Insulatard® , Mixtard® 30 vial / NovoLet® insulin human ErgoPen®2 type 1 type 2 diabetes treatment , eligible study physician take decision use study insulin product study device Subjects treat Actrapid® Penfill® , Insulatard® Penfill® , Mixtard® 30 Penfill® NovoPen®3 Actrapid® FlexPen® , Insulatard® FlexPen® , Mixtard® 30 FlexPen® 4 week inclusion study Subjects previously enrol study Subjects hypersensitivity insulin human excipients Women pregnant , breast feeding intention become pregnant within next 6 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>